Destiny Pharma
Skip to content
  • About Us
    • Board of Directors
    • Leadership
    • Scientific Advisory Board
    • History
  • Pipeline
    • NTCD-M3 for Clostridioides difficile Infections
    • XF-73 Nasal for Post Surgical Infections
    • XF-73 for Dermal Infections
    • SPOR-COV™ for COVID-19
    • XF Research Programs
  • Target Markets
    • Clostridioides difficile Infections
    • Post Surgical Infections
    • Dermal Infections
    • COVID-19
    • Anti-Microbial Resistance
  • Our Technologies
    • Biotherapeutics
      • NTCD-M3
      • SPOR-COV™
    • XF Platform
  • Business Development
  • News
  • Investors
    • AIM Rule 26
    • Corporate Governance
    • Share Price Information
    • Regulatory News
    • Constitutional Documents
    • Reports & Presentations
    • Advisers / Shareholder Contacts
    • Analyst Coverage
    • Email Alerts
  • Contact
    • Careers
    • Useful Links

Archive 2016

2016
  • - 16 Dec 2016 – 21st Century Cures Act signed into law by President Obama
  • - 30 Nov 2016 – Destiny Pharma CEO appointed to the board of GAMRIF
  • - 31 Oct 2016 – Wellcome Trust report on boosting development of new antimicrobial drugs
  • - Destiny Pharma to attend IDWeek in New Orleans, Louisiana
  • - 21 Sep 2016 – Momentous Step taken by UN to Fight Antibiotic Resistance welcomed by Destiny Pharma
  • - 05 Sep 2016 – Press Release: Novel Antibacterial Drug, exeporfinium chloride, Delivers Encouraging Safety, Tolerability and Efficacy Data in US Clinical Trial
  • - Destiny Pharma Expert View Published in The Pharma Letter
  • - Destiny Pharma invited to present at the inaugural Superbugs & Superdrugs USA Conference & Exhibition on the 14th and 15th November 2016 in New Jersey, USA
  • - 19 May 2016 – Destiny Pharma Welcomes O’Neill Report on Tackling Antimicrobial Resistance (AMR)
  • - 18 Mar 2016 – Destiny Pharma: ‘In the News.’
  • - 26 Jan 2016 – Destiny Pharma sign Declaration to fight antibiotic resistance

Archive

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

Destiny Pharma

© All rights reserved.

Powered by WordPress

Destiny Pharma plc
Sussex Innovation Centre
Science Park Square
Brighton
BN1 9SB
UK

Tel: +44(0) 1273 704440

Registered Company
No. 3167025
About Us
Pipeline
Target Markets
Our Technologies
Business Development
News
Investors
Contact
Terms of Use
Privacy Statement